In the Suppression of Ovarian Function Trial (SOFT) Trial

Suppression of Ovarian Function Trial (SOFT) Trial

  • In the Suppression of Ovarian Function Trial (SOFT) trial:
    • Ovarian function suppression given for five years reduced disease-free survival (DFS) events when added to 5 years of adjuvant tamoxifen:
      • 78.9% to 83.2% DFS at 8 years, hazard ratio (HR) of 0.76, P = .009
    • One-third of women entered in the SOFT trial were randomized to receive the aromatase inhibitor exemestane plus ovarian function suppression:
      • They had an even better disease-free survival
  • References:
  • Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Eng J Med. 2018;379(2):122-137.
  • Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436-446.

#Arrangoiz #CancerSurgeon #BreastSurgeon #SurgicalOncologist @CASO @CenterforAdvancedSurgicalOncology #BreastCancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s